Friday, 12 June 2026

Vol. 1 · No. 10 Friday, 12 June 2026 “The gap between phase two and phase three is where enthusiasm meets evidence.”

In this edition

Today's edition leads with the FDA's approval of belzutifan plus pembrolizumab as the first adjuvant combination for high-risk clear-cell renal cell carcinoma — a milestone pairing HIF-2α inhibition with checkpoint blockade in the post-surgical setting. Elsewhere: every participant in the LASSARAB Phase 1 trial seroconverted against Lassa fever; U.S. measles cases reach 2,073 across 40 jurisdictions ahead of a November elimination review; a Nature paper shows fatal paediatric brain tumours are wired into functional brain networks; INTEGRATE IIb finds RegoNivo does not extend survival in refractory gastroesophageal cancer (HR 0.88, p=0.23); and Johnson & Johnson acquires Firefly Bio for $1 billion to gain a KRAS-targeting degrader-antibody conjugate platform co-founded with Nobel laureate Carolyn Bertozzi.

FDA & Regulatory

FDA Approves Belzutifan Plus Pembrolizumab as First Adjuvant Combination Therapy for High-Risk Clear-Cell Renal Cell Carcinoma

The approval of belzutifan (Welireg) plus pembrolizumab (Keytruda) marks the first HIF-2α inhibitor cleared in the adjuvant setting and the first combination to pair PD-1 checkpoint blockade with upstream HIF pathway inhibition after surgery for kidney cancer.

Marcus Webb, FDA & Regulatory Desk · 2 min read

The Food and Drug Administration approved belzutifan (Welireg) in combination with pembrolizumab (Keytruda) today as adjuvant therapy for adults with clear-cell renal cell carcinoma at high risk of recurrence following nephrectomy, marking the first approval of a HIF-2α inhibitor in any post-surgical cancer setting.

The approval is based on LITESPARK-022 (NCT05239728), a randomised, double-blind, placebo-controlled Phase 3 trial in which patients who had undergone nephrectomy for high-risk ccRCC were randomised to belzutifan plus pembrolizumab or placebo plus pembrolizumab. The primary endpoint was disease-free survival. The combination produced a statistically significant DFS improvement: hazard ratio 0.72 (95% CI 0.59–0.87), a 28% reduction in the risk of recurrence or death compared with pembrolizumab plus placebo.

Continue reading →

Also leading today

Research

First-in-Human Lassa Fever Vaccine Reports 100% Seroconversion in Phase 1 Trial

LASSARAB, an inactivated rabies virus engineered to carry the Lassa glycoprotein, induced anti-Lassa IgG antibodies in every participant who completed a two-dose regimen — the first Phase 1 data for this rabies-vectored candidate and a signal for a disease with no licensed vaccine.

Elena Torres, Research Desk · 2 min

Research

Fatal Paediatric Brain Tumours Are Wired Into the Brain — Disrupting That Network May Extend Survival

A Nature study shows that diffuse midline gliomas integrate into the brain's functional connectivity networks in ways that shape survival — and identifies a narrow surgical window for a small subset of patients with thalamic tumours outside the brainstem.

Elena Torres, Research Desk · 2 min

Trials Today

Phase III INTEGRATE IIb: Regorafenib + nivolumab vs. chemotherapy in refractory gastro-oesophageal adenocarcinoma (n=462) — Negative primary endpoint — OS HR 0.88 (95% CI 0.71–1.09; p=0.23). Results reported at ESMO 2025 LBA80.
Phase III DREAMS-3: Chemotherapy ± durvalumab in perioperative oesophageal/GEJ adenocarcinoma (n=412) — Results expected Q4 2026. Would establish PD-L1 blockade in the perioperative GEJ setting if positive.
Phase III DANHEART: Empagliflozin vs. placebo in arrhythmogenic and dilated cardiomyopathy (n=400) — Enrolment ongoing. First SGLT2i trial in inherited cardiomyopathy; composite HF event primary endpoint.
Phase II miRisten (MRX34): miRNA mimic in AML — FDA clinical hold reinstated June 2026 — Two Grade 4 immune-mediated AEs triggered hold reinstatement. Protocol amendment pending before enrolment resumes.

At the Agencies

Belzutifan + pembrolizumab approved for adjuvant high-risk ccRCC — first HIF-2α inhibitor in any adjuvant oncology indication — LITESPARK-022. DFS HR 0.72 (95% CI 0.59–0.87). Approved June 12, 2026.
Cytisinicline NDA PDUFA June 20 — first new smoking-cessation pharmacotherapy since varenicline (2006) — Achieve Life Sciences. ORCA-3 continuous quit rate 30.3% vs 9.4%. BTD held for vaping cessation (separate indication).
Nitenpyram EUA for pet dogs and cats in New World screwworm-threatened zones — effective June 11, 2026 — USDA-coordinated. First federal emergency use authorisation for a veterinary antiparasitic in a screwworm response.

Who's Who

Carolyn Bertozzi

2022 Nobel Laureate in Chemistry; Co-Founder, Firefly Bio

Stanford chemist whose click chemistry and bioorthogonal reaction work underpins Firefly Bio's Firelink degrader-antibody conjugate platform, acquired by J&J for $1 billion today.

The story →

On the Wire

Osimertinib With or Without Bevacizumab as Initial... 10 days ago
FDA Issues Draft Guidance to Help Accelerate Cell and... 10 days ago
Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve... 10 days ago
DKK1 and CKAP4 expression is associated with cervical... 12 days ago
IMU Biosciences nabs $53M funding round to ‘decode’ the... 9 days ago
Flex Appeal: Evaluating the Efficacy of Anesthetic... 10 days ago
NHS consultants are "quiet quitting," senior doctors... 10 days ago

Full wire (160) →

In brief

Research Preliminary Data: Artemisinin-Resistance Mutation Has Swept to 79% in Western Zambia, With Day-3 Positivity 28 Times Higher Than Eastern Zambia A preprint reports that the pfKelch13 C580Y mutation — the genetic marker of artemisinin partial resistance — has reached 79% prevalence in Western Province samples, with treated patients showing 28% day-3 parasite positivity versus 0% in eastern Zambia. Not peer reviewed.
Clinical Trials RegoNivo Fails to Extend Survival in Phase 3 Gastric Cancer Trial, Deflating Early-Phase Enthusiasm INTEGRATE IIb, a 462-patient randomised trial in refractory gastro-oesophageal adenocarcinoma, found that adding nivolumab to regorafenib did not produce a statistically significant improvement in overall survival (HR 0.88, 95% CI 0.71–1.09; p=0.23), ending an exploration launched by a 44% response rate in a small Phase 1b study.
Public Health U.S. Measles Cases Reach 2,073 Across 40 Jurisdictions — Elimination Status at Risk Before November Review The CDC's June 11 update puts the 2026 case count at 2,073, the highest since 1992. The Pan American Health Organization will formally review North American measles elimination status in November — the first time the U.S. has faced such scrutiny since 2000.
Biotech Business J&J to Acquire Firefly Bio for $1 Billion, Gaining Nobel Laureate-Backed KRAS-Targeting Degrader Antibody Conjugate Platform The deal brings J&J the preclinical Firelink platform — which uses protein degraders instead of cytotoxins as antibody payloads — co-founded with Nobel Prize chemist Carolyn Bertozzi and aimed at KRAS-mutant tumours.
FDA & Regulatory FDA Decision Due June 20 on Cytisinicline — First New Smoking-Cessation Drug Since Varenicline in 2006 Achieve Life Sciences faces a June 20 PDUFA date for cytisinicline, a plant-derived nicotinic receptor partial agonist used in Eastern Europe for six decades that met primary endpoints in two Phase 3 U.S. trials, with ORCA-3 showing a 30.3% vs 9.4% continuous quit rate versus placebo.

← The archive

Friday, 12 June 2026 edition — The Vital Record

FDA Approves Belzutifan Plus Pembrolizumab as First Adjuvant Combination Therapy for High-Risk Clear-Cell Renal Cell Carcinoma

Also leading today

First-in-Human Lassa Fever Vaccine Reports 100% Seroconversion in Phase 1 Trial

Fatal Paediatric Brain Tumours Are Wired Into the Brain — Disrupting That Network May Extend Survival

In brief